Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Omeros Corporation (NASDAQ: OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and ...
Pharmaceutical Technology on MSN
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.
A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
Human interleukin-26 (IL-26) is linked to intestinal inflammation and is bactericidal in vitro. This study uses zebrafish as a model to identify a role of IL-26 in shaping gut microbiota composition, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback